Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30043388HIVENSG00000160551.12protein_codingTAOK1NoNo57551Q7L7X3
TVIS30021363HIVENSG00000160551.12protein_codingTAOK1NoNo57551Q7L7X3
TVIS30043389HIVENSG00000160551.12protein_codingTAOK1NoNo57551Q7L7X3
TVIS30043390HIVENSG00000160551.12protein_codingTAOK1NoNo57551Q7L7X3
TVIS30043391HIVENSG00000160551.12protein_codingTAOK1NoNo57551Q7L7X3
TVIS30043392HIVENSG00000160551.12protein_codingTAOK1NoNo57551Q7L7X3
TVIS30043393HIVENSG00000160551.12protein_codingTAOK1NoNo57551Q7L7X3
TVIS30043394HIVENSG00000160551.12protein_codingTAOK1NoNo57551Q7L7X3
TVIS30043395HIVENSG00000160551.12protein_codingTAOK1NoNo57551Q7L7X3
TVIS30043396HIVENSG00000160551.12protein_codingTAOK1NoNo57551Q7L7X3
TCGA Plot Options
Drug Information
GeneTAOK1
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0009392
UniProt IDQ7L7X3
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830